CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

anti-SARS-CoV-2 plasmaWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug1482 Isoprinosine Wiki 1.00
drug1565 Levamisole and Isoprinosine Wiki 1.00
drug1563 Levamisole Wiki 1.00
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Randomized, Double-blind, Placebo-controlled Trial of Anti-SARS-CoV-2 Plasma in Hospitalized Non-ICU Patients With COVID-19

The purpose of this study is to assess the efficacy and safety of the administration of anti-SARS-CoV-2 convalescent plasma in COVID-19 patients who are sick enough to warrant hospitalization, but not yet admitted to the ICU (prior to the onset of overwhelming disease including a systemic inflammatory response, sepsis, and/or ARDS).

NCT04467151 COVID-19 Drug: anti-SARS-CoV-2 plasma Other: Placebo

Primary Outcomes

Description: Disease progression from the state at randomization (with a "3" or "4" on the WHO Ordinal Scale for Clinical Improvement) to requiring invasive mechanical ventilation (which is "6" or greater on the WHO scale) during the study period

Measure: Disease progression measured by WHO scale

Time: Day 0 through Day 28 (or hospital discharge)

Secondary Outcomes

Description: Comparison of the number of participants reaching a maximum daily WHO score of 5, 7, and 8 during the study period per group

Measure: Comparison of maximum WHO score per group

Time: Day 0 through Day 28 (or hospital discharge)

Description: Comparison of the median and maximum daily WHO scores during the study period per group

Measure: Comparison of decrease of median and maximum WHO score per group

Time: Day 0 through Day 28 (or hospital discharge)

Description: Comparison of time to clinical improvement, defined as time between randomization and time to improvement (WHO Ordinal Scale "2" first reached for at least 1 day)

Measure: Comparison of time to clinical improvement per group

Time: Day 0 through Day 28 (or hospital discharge)

Description: Evaluate the time to reach score of at least 6 within 28 days

Measure: Comparison of time to reach score of "6" or greater on the WHO scale

Time: Day 0 through Day 28 (or hospital discharge)

Other Outcomes

Description: Evaluate number of days hospitalized

Measure: Comparison of hospital length of stay per group

Time: Day 0 through Day 28 (or hospital discharge)

Description: Evaluate number of hours in the ICU

Measure: Comparison of ICU length of stay per group

Time: Day 0 through Day 28 (or hospital discharge)

No related HPO nodes (Using clinical trials)